Skip to main content
. 2023 Feb 24;22(1):75–85. doi: 10.2450/BloodTransfus.485

Figure 2.

Figure 2

Comparison of mean changes in global pancreas T2* values between the combined treatment and deferiprone monotherapy groups (upper panel) and between the combined treatment and deferasirox monotherapy groups (lower panel) in patients with baseline global pancreas T2* value <26 ms

The *symbol indicates that the p-value was adjusted for baseline global pancreas T2* values.

DFP: deferiprone; DFO: desferrioxamine; DFX: deferasirox.